Ceruvia Raises $8 Million to Complete Integrated Phase 1/2 Trial of Proprietary Non-Hallucinogenic LSD Analog for Cluster Headache

Phase 1Non-Hallucinogenic LSD AnalogPositive

AI Analysis

Summary

Ceruvia Lifesciences announced an $8 million founder-backed investment to advance its integrated Phase 1/2 trial of a proprietary non-hallucinogenic LSD analog for cluster headache treatment. The funding will support accelerated clinical development through a fully funded trial program.

Clinical Trial Data

Phase

1/2

Importance:5/10

Sentiment:

0.60

fundingclinical developmentneurotransformationalcluster headacheLSD analogPhase 1/2 trial

Related Companies

$INBP $GLSI

Read the original article

Published by PR Newswire Biotech on August 3, 2026 2:00 PM

Read Original